Matthew Gall Buys 5,000 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) Stock

iTeos Therapeutics, Inc. (NASDAQ:ITOS) CFO Matthew Gall bought 5,000 shares of the company’s stock in a transaction on Tuesday, November 19th. The shares were bought at an average price of $7.73 per share, for a total transaction of $38,650.00. Following the transaction, the chief financial officer now owns 65,429 shares of the company’s stock, valued at approximately $505,766.17. This represents a 8.27 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

iTeos Therapeutics Stock Up 0.3 %

Shares of NASDAQ:ITOS traded up $0.02 on Tuesday, hitting $7.90. The company had a trading volume of 444,714 shares, compared to its average volume of 443,252. The firm’s 50-day simple moving average is $9.96 and its two-hundred day simple moving average is $13.96. The firm has a market capitalization of $288.59 million, a price-to-earnings ratio of -2.51 and a beta of 1.39. iTeos Therapeutics, Inc. has a 1 year low of $7.66 and a 1 year high of $18.75.

iTeos Therapeutics (NASDAQ:ITOS) last announced its earnings results on Tuesday, November 12th. The company reported ($1.05) EPS for the quarter, beating analysts’ consensus estimates of ($1.18) by $0.13. Equities research analysts anticipate that iTeos Therapeutics, Inc. will post -3.57 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on ITOS. JPMorgan Chase & Co. lowered their price objective on iTeos Therapeutics from $27.00 to $24.00 and set an “overweight” rating on the stock in a research report on Monday, August 12th. HC Wainwright restated a “buy” rating and issued a $46.00 target price on shares of iTeos Therapeutics in a research note on Friday. Wedbush reiterated an “outperform” rating and set a $25.00 price target on shares of iTeos Therapeutics in a research report on Tuesday, November 12th. Finally, Wells Fargo & Company assumed coverage on shares of iTeos Therapeutics in a research report on Tuesday, August 13th. They issued an “overweight” rating and a $31.00 price objective on the stock.

Hedge Funds Weigh In On iTeos Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. The Manufacturers Life Insurance Company grew its stake in shares of iTeos Therapeutics by 6.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,071 shares of the company’s stock worth $164,000 after buying an additional 690 shares during the last quarter. Creative Planning increased its holdings in shares of iTeos Therapeutics by 6.5% during the third quarter. Creative Planning now owns 19,636 shares of the company’s stock valued at $200,000 after acquiring an additional 1,196 shares in the last quarter. nVerses Capital LLC boosted its stake in iTeos Therapeutics by 212.5% in the 3rd quarter. nVerses Capital LLC now owns 2,500 shares of the company’s stock worth $26,000 after purchasing an additional 1,700 shares in the last quarter. Public Employees Retirement System of Ohio grew its position in iTeos Therapeutics by 4.9% during the 1st quarter. Public Employees Retirement System of Ohio now owns 39,003 shares of the company’s stock valued at $532,000 after purchasing an additional 1,817 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its stake in iTeos Therapeutics by 60.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,024 shares of the company’s stock valued at $72,000 after purchasing an additional 2,646 shares in the last quarter. Institutional investors own 97.16% of the company’s stock.

iTeos Therapeutics Company Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.